Skip to main content
Signal8

NORTHWEST BIOTHERAPEUTICS INC (NWBO)

Northwest Biotherapeutics, Inc. (NWBO) is a biotechnology firm that creates personalized immune-based treatments for various cancers, operating both within the United States and internationally. Their product pipeline relies on DCVax, a proprietary technology platform. This platform harnesses a patient's own activated dendritic cells to stimulate their immune system to combat cancerous cells. The company's leading therapeutic candidate, DCVax-L, has successfully completed Phase III clinical trials targeting Glioblastoma multiforme, an aggressive form of brain cancer. Additionally, Northwest Biotherapeutics is progressing DCVax-Direct through Phase I/II clinical studies, focusing on the treatment of inoperable solid tumors. Founded in 1996, the company's headquarters are situated in Bethesda, Maryland.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Northwest Biotherapeutics, Inc. logo

Northwest Biotherapeutics, Inc.

OTC:NWBOHealthcare
+2.12%$0.1493
Mkt Cap$270.53M
EV-
Float1.78B
O/S1.81B
VOL5.2M sh
$ Vol$753K
RVOL1.17×
Inst Own0.1%
SI3.9%
Net Cash/Sh-
Dilution
Northwest Biotherapeutics, Inc. logoOTC:NWBO$0.1493+2.12%
FormDescription
10-Q
8-K
10-Q
8-K
424B5
8-K
7.01
10-Q
EFFECT
Notice of Effectiveness
POS AM
Post-Effective Amendment
10-K
Annual Report
8-K
2.01
NT 10-K
SEC Filing
8-K
8.01
8-K
5.03,5.07,9.01
DEF 14A
Definitive Proxy Statement
EFFECT
Notice of Effectiveness
424B5
Prospectus Supplement
CORRESP
SEC Filing
8-K
1.01,2.03
PRE 14A
Preliminary Proxy Statement
10-Q
Quarterly Report
8-K
1.01,2.03
8-K
1.01
8-K
8.01
S-3
Shelf Registration Statement

1-25 of 804

…

Recent SEC filings with analysis

    Northwest Biotherapeutics Inc. (NWBO) SEC Filings | Signal8